Peter Young is a consultant interested in the human-centred design, strategy, governance, risk, and organisational transformation of service providers. He has been a member of the Board of a NSW metropolitan Local Health District and a member of the NSW Health Ministerial Advisory Committee.
Peter was diagnosed with NSCLC in 2020, for which he initially received chemotherapy and immunotherapy, which in time proved highly toxic and was discontinued. In the search for an alternate treatment, Peter underwent some genetic testing, which detected a RET fusion and led him into the expanded access program of a clinical trial of a particular targeted therapy.
Peter is particularly interested in the patient pathway through lung cancer management and improving the patient experience of clinical management.
